Grant: CIHR Fellowship
Direct Payment
$100,000.00
Enhancing Heart Transplant Success: Extending Preservation Time through Mitigating Mitochondrial Injury using Partial Freezing and Therapeutic Interventions
EF 2023-24
Résumé
Cardiovascular diseases are the leading global cause of death, as highlighted by the WHO, with advanced heart failure being a primary contributor. For many, a heart transplant is the only solution. Yet, there's a critical shortage of donor hearts, and many patients die waiting. Presently, hearts are stored and transported using 'static cold storage', which gives only a 4-6 hour window before the heart can no longer be transplanted. Currently, the clinical method of storage and transporting these hearts, known as 'static cold storage', offers a mere 4-6-hour window before the heart becomes non-viable for transplant. While methods like machine perfusion (MP) slightly prolong this timeframe, the improvements aren't significant. Our lab, under Dr. Tessier, has made significant strides with a new technique: partial freezing (PF). Utilizing special chemicals called cryoprotectant agents (CPA) and cooling temperatures below 0 Celsius, we can store organs, like rat livers, in a frozen but usable state for up to five times longer. However, concerns about CPAs' effects on mitochondria are significant, as damage to these cellular powerhouses can amplify stress and post-transplant injury. Our preliminary results have standardized a protocol showing effectiveness of two CPAs mixes. I will be fine-tuning this protocol for two CPAs and temperatures on excised rat hearts. I will assess excised heart health in this step via measuring lactate and mitochondrial injury markers such as cytochrome c (cyt c). Following this, I will treat the hearts with two mitochondrial protective drugs: Mito Q and Cyclosporin A by adding them to our CPA mix. These drugs counteract oxidative stress and cellular damage via cyt c respectively, potentially enhancing storage thereby transportation time. Ultimately enhancing mitochondrial health and reducing damage during this method could ultimately extend transport time to increase the chances of successful transplants, bridging the donor-recipient gap.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
493005
Name
Singh Gurjit
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Fellowships - Post-PhD
Projecttitle
Enhancing Heart Transplant Success: Extending Preservation Time through Mitigating Mitochondrial Injury using Partial Freezing and Therapeutic Interventions
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cryobiology; Donor Heart Preservation; Drug Interventions; End Stage Heart Failure; Heart Transplants; Machine Perfusion; Mitochondrial Injury And Health; Partial Freezing
Abstract
Cardiovascular diseases are the leading global cause of death, as highlighted by the WHO, with advanced heart failure being a primary contributor. For many, a heart transplant is the only solution. Yet, there's a critical shortage of donor hearts, and many patients die waiting. Presently, hearts are stored and transported using 'static cold storage', which gives only a 4-6 hour window before the heart can no longer be transplanted. Currently, the clinical method of storage and transporting these hearts, known as 'static cold storage', offers a mere 4-6-hour window before the heart becomes non-viable for transplant. While methods like machine perfusion (MP) slightly prolong this timeframe, the improvements aren't significant. Our lab, under Dr. Tessier, has made significant strides with a new technique: partial freezing (PF). Utilizing special chemicals called cryoprotectant agents (CPA) and cooling temperatures below 0 Celsius, we can store organs, like rat livers, in a frozen but usable state for up to five times longer. However, concerns about CPAs' effects on mitochondria are significant, as damage to these cellular powerhouses can amplify stress and post-transplant injury. Our preliminary results have standardized a protocol showing effectiveness of two CPAs mixes. I will be fine-tuning this protocol for two CPAs and temperatures on excised rat hearts. I will assess excised heart health in this step via measuring lactate and mitochondrial injury markers such as cytochrome c (cyt c). Following this, I will treat the hearts with two mitochondrial protective drugs: Mito Q and Cyclosporin A by adding them to our CPA mix. These drugs counteract oxidative stress and cellular damage via cyt c respectively, potentially enhancing storage thereby transportation time. Ultimately enhancing mitochondrial health and reducing damage during this method could ultimately extend transport time to increase the chances of successful transplants, bridging the donor-recipient gap.
Competitiondate
202310
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Singh, Gurjit
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~